Advanced Proteome Therapeutics Corporation (APTCF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Advanced Proteome Therapeutics Corporation (APTCF) trades at $0.0002 with AI Score 44/100 (Grade C). Advanced Proteome Therapeutics Corporation is a biotechnology company focused on developing and commercializing a platform for chemical modification of protein therapeutics. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for APTCF: APTCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates APTCF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
APTCF: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Advanced Proteome Therapeutics Corporation (APTCF) Healthcare & Pipeline Overview
Advanced Proteome Therapeutics Corporation is a biotechnology firm specializing in protein therapeutic modification, focusing on antibody drug conjugates and immunomodulation. Operating in the competitive biotechnology sector, the company aims to commercialize its platform for enhanced protein therapeutics, targeting applications in oncology and immune-related diseases.
What Is the Investment Thesis for APTCF?
Advanced Proteome Therapeutics Corporation presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's proprietary platform for chemical modification of protein therapeutics could unlock significant value if successfully commercialized. Key value drivers include successful preclinical and clinical validation of its ADC technology and strategic partnerships with larger pharmaceutical companies. Growth catalysts include advancement of its ADC candidates through clinical trials and potential FDA approval. However, the company faces significant risks, including regulatory hurdles, competition from established biotechnology firms, and the need for additional funding. Given the company's early stage of development and OTC market listing, investors should carefully consider the risks and potential rewards before investing. The company's P/E ratio is 0.0 and Beta is 1.41 as of 2026-03-18.
Based on FMP financials and quantitative analysis
APTCF Key Highlights
- Focus on antibody drug conjugates (ADCs) offers targeted cancer therapy potential.
- Proprietary platform for chemical modification of protein therapeutics provides a competitive advantage.
- Headquartered in Canada, providing access to North American markets.
- Early-stage biotechnology company with potential for significant growth if platform is validated.
- Trades on the OTC market, indicating higher risk and volatility.
Who Are APTCF's Competitors?
APTCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HOPHF Hemogenyx Pharmaceuticals Plc | $2.33 | +0.00% | $15.8M | 52 |
| HURA TuHURA Biosciences, Inc. | $2.24 | -0.44% | $143M | 46 |
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.34 | -1.27% | $221M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are APTCF's Key Strengths?
- Proprietary platform for chemical modification of protein therapeutics.
- Focus on high-growth area of antibody drug conjugates (ADCs).
- Potential for strategic partnerships with larger pharmaceutical companies.
- Experienced scientific team.
What Are APTCF's Weaknesses?
- Early-stage company with limited revenue and resources.
- Reliance on successful development and commercialization of its platform.
- High regulatory hurdles and clinical trial risks.
- Trades on the OTC market, indicating higher risk and lower liquidity.
What Could Drive APTCF Stock Higher?
- Advancement of ADC candidates into Phase 1 clinical trials (Timeline: 6-12 months).
- Continued research and development efforts to expand the company's platform.
- Potential for strategic partnerships with larger pharmaceutical companies.
- Presentation of preclinical data at scientific conferences (Timeline: Quarterly).
- Grant funding opportunities to support research and development.
What Are the Key Risks for APTCF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for its ADC candidates.
- Competition from established biotechnology and pharmaceutical companies.
- Need for additional funding to support research and development activities.
- Unfavorable changes in the regulatory environment.
- Limited liquidity due to trading on the OTC market.
What Are the Growth Opportunities for APTCF?
- Expansion of ADC Pipeline: Advanced Proteome Therapeutics can expand its pipeline of antibody-drug conjugate (ADC) candidates targeting various cancer types. The global ADC market is projected to reach $29.4 billion by 2028, growing at a CAGR of 22.7% from 2021. Successful development and commercialization of new ADC candidates would significantly increase the company's revenue potential. Timeline: 3-5 years for clinical trials and potential FDA approval.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its protein therapeutic platform. Collaborations can provide financial resources, expertise, and access to established distribution networks. The pharmaceutical industry is increasingly seeking partnerships with innovative biotechnology companies to enhance their drug development pipelines. Timeline: Ongoing; partnerships can be established at any time.
- Licensing Agreements: Licensing its proprietary platform for chemical modification of protein therapeutics to other biotechnology and pharmaceutical companies. Licensing agreements can generate upfront payments, milestone payments, and royalties on future sales of products developed using the platform. This provides a non-dilutive source of revenue and expands the reach of the company's technology. Timeline: Ongoing; licensing opportunities can arise at any time.
- Expansion into Immunomodulation: Expanding the application of its platform to develop novel immunomodulatory therapies. The immunomodulation market is growing rapidly, driven by the increasing prevalence of autoimmune diseases and the demand for personalized medicine. Advanced Proteome Therapeutics can leverage its expertise in protein modification to create targeted immunomodulatory agents. Timeline: 2-4 years for preclinical and early clinical development.
- Geographic Expansion: Expanding its operations and partnerships into new geographic markets, particularly in Europe and Asia. These regions offer significant growth opportunities due to their large populations and increasing healthcare spending. Establishing a presence in these markets would diversify the company's revenue streams and reduce its reliance on the North American market. Timeline: 1-3 years for establishing partnerships and regulatory approvals.
What Opportunities Does APTCF Have?
- Expanding ADC pipeline to target various cancer types.
- Licensing its platform to other biotechnology and pharmaceutical companies.
- Entering into strategic partnerships for co-development and commercialization.
- Expanding into immunomodulation applications.
What Threats Does APTCF Face?
- Competition from established biotechnology and pharmaceutical companies.
- Failure to obtain regulatory approvals for its products.
- Lack of funding to support research and development activities.
- Unfavorable changes in the regulatory environment.
What Are APTCF's Competitive Advantages?
- Proprietary Technology Platform: The company's platform for chemical modification of protein therapeutics is protected by patents and trade secrets, creating a barrier to entry for competitors.
- Expertise in Protein Modification: The company has a team of experienced scientists and engineers with expertise in protein chemistry and drug development.
- Focus on Antibody Drug Conjugates: The company's focus on ADCs positions it in a high-growth market with significant unmet medical needs.
- Strategic Partnerships: Collaborations with larger pharmaceutical companies can provide access to resources and expertise that smaller companies may lack.
What Does APTCF Do?
Advanced Proteome Therapeutics Corporation, headquartered in Burnaby, Canada, operates through its subsidiary, Advanced Proteome Therapeutics Inc., as a biotechnology company. The company is dedicated to the development and commercialization of a proprietary platform designed for the chemical modification of protein therapeutics. This platform is primarily focused on applications within the field of antibody drug conjugates (ADCs), protein conjugates, and immunomodulation. The company's core technology aims to enhance the efficacy and safety profiles of protein-based therapeutics. By chemically modifying proteins, Advanced Proteome Therapeutics seeks to create more targeted and effective treatments for various diseases. The company's research and development efforts are centered on leveraging its platform to generate novel therapeutic candidates. Advanced Proteome Therapeutics is strategically positioned to capitalize on the growing demand for advanced protein therapeutics, particularly in oncology and immune-related disorders. The company's focus on ADCs reflects the increasing interest in targeted cancer therapies that deliver cytotoxic agents directly to tumor cells, minimizing systemic toxicity. The company continues to explore opportunities to expand its platform and pipeline through strategic partnerships and collaborations.
What Products and Services Does APTCF Offer?
- Develops a platform for chemical modification of protein therapeutics.
- Focuses on antibody drug conjugates (ADCs) for targeted cancer therapy.
- Works on protein conjugates for enhanced drug delivery.
- Explores immunomodulation applications for immune-related diseases.
- Conducts research and development to create novel therapeutic candidates.
- Aims to improve the efficacy and safety of protein-based therapeutics.
How Does APTCF Make Money?
- Develops and patents a proprietary technology platform for protein modification.
- Out-licenses its technology to other pharmaceutical companies for upfront and milestone payments, plus royalties.
- Develops its own pipeline of ADC drug candidates for specific oncology targets.
- Seeks strategic partnerships with larger pharmaceutical companies for co-development and commercialization.
What Industry Does APTCF Operate In?
Advanced Proteome Therapeutics operates within the dynamic and competitive biotechnology industry. The market for protein therapeutics, particularly antibody drug conjugates, is experiencing substantial growth, driven by the increasing demand for targeted therapies in oncology and immunology. The competitive landscape includes established biotechnology companies and pharmaceutical giants, such as ALDNF (Almaden Minerals Ltd.), EDNEF (Endonovo Therapeutics Inc.), HOPHF (Hope Biosciences Holding Inc.), HURA (Huron BioProducts Inc.), and MMNFF (MedMen Enterprises Inc.), all vying for market share. Advanced Proteome Therapeutics aims to differentiate itself through its proprietary platform for chemical modification of protein therapeutics.
Who Are APTCF's Key Customers?
- Pharmaceutical companies seeking to enhance their drug development pipelines.
- Biotechnology companies looking for innovative protein modification technologies.
- Patients who may benefit from more effective and targeted therapies.
- Research institutions interested in collaborating on protein therapeutic development.
Company Profile
Advanced Proteome Therapeutics Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Burnaby, CA. The company is led by CEO Benjamin Krantz. APTCF has traded publicly since 2009.
How Advanced Proteome Therapeutics Corporation Is Valued
Relative to its peer group, APTCF's quantitative score of 44/100 is below the peer average of 63/100.
ROE 198%Key Financial Metrics
Return on equity for Advanced Proteome Therapeutics Corporation stands at 198.2%, a gauge of how efficiently it converts shareholder capital into profit. APTCF trades at a trailing price-to-earnings ratio of 0.01, below the Healthcare sector average of ~23x. A current ratio of 0.50 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 3/9Financial Health
Advanced Proteome Therapeutics Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
APTCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary platform for chemical modification of protein therapeutics.
- Focus on high-growth area of antibody drug conjugates (ADCs).
- Potential for strategic partnerships with larger pharmaceutical companies.
- Experienced scientific team.
Bear Case
- Early-stage company with limited revenue and resources.
- Reliance on successful development and commercialization of its platform.
- High regulatory hurdles and clinical trial risks.
- Trades on the OTC market, indicating higher risk and lower liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
APTCF Latest News
No recent news available for APTCF.
APTCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for APTCF.
Price Targets
Wall Street price target analysis for APTCF.
APTCF MoonshotScore
What does this score mean?
The MoonshotScore rates APTCF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Benjamin Krantz
CEO
Benjamin Krantz serves as the Chief Executive Officer of Advanced Proteome Therapeutics Corporation. His background includes experience in the biotechnology sector, with a focus on corporate strategy and business development. Krantz has a track record of leading early-stage companies and driving innovation in the pharmaceutical industry. His expertise lies in identifying and capitalizing on emerging trends in the healthcare market. He is responsible for overseeing the company's overall strategic direction and ensuring its long-term growth.
Track Record: Under Benjamin Krantz's leadership, Advanced Proteome Therapeutics has focused on advancing its proprietary platform for chemical modification of protein therapeutics. Key milestones include securing patents for its technology and initiating preclinical studies for its ADC candidates. Krantz has also been instrumental in establishing partnerships with research institutions and exploring potential collaborations with pharmaceutical companies. His strategic decisions have positioned the company for future growth and success.
APTCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Advanced Proteome Therapeutics Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Trading on the OTC Other tier is generally associated with higher risk and greater price volatility compared to stocks listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Limited Financial Disclosure: Lack of publicly available financial information makes it difficult to assess the company's financial health and performance.
- Low Liquidity: Limited trading volume and wide bid-ask spreads can result in difficulty buying or selling shares.
- Higher Volatility: OTC stocks are generally more volatile than stocks listed on major exchanges.
- Regulatory Scrutiny: OTC companies may be subject to less regulatory oversight than exchange-listed companies.
- Potential for Fraud: The OTC market is more susceptible to fraudulent activities due to lower listing standards.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues involving the company.
- Monitor the company's news releases and investor relations materials.
- Consult with a qualified financial advisor before investing.
- Presence of a functional website with detailed information about the company.
- Experienced management team with relevant industry expertise.
- Patents or other intellectual property protecting its technology.
- Strategic partnerships with reputable organizations.
- Positive news coverage or industry recognition.
APTCF Healthcare Stock FAQ
What does the AI Score mean for APTCF?
APTCF holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Advanced Proteome Therapeutics Corporation is a biotechnology company focused on developing and commercializing a platform for chemical modification of protein therapeutics. The company's …
What does Advanced Proteome Therapeutics Corporation do?
Advanced Proteome Therapeutics Corporation is a biotechnology company focused on developing and commercializing a platform for the chemical modification of protein therapeutics. Their primary focus is on antibody-drug conjugates (ADCs), which are designed to deliver cytotoxic agents directly to cancer cells, minimizing harm to healthy tissues.
What do analysts say about APTCF stock?
As of 2026-03-18, there is no readily available analyst coverage for Advanced Proteome Therapeutics Corporation (APTCF) due to its OTC market listing and early stage of development. Key valuation metrics, such as price targets and earnings estimates, are not widely available.
What are the main risks for APTCF?
The main risks for Advanced Proteome Therapeutics Corporation include regulatory hurdles, competition from established biotechnology firms, and the need for additional funding. The company's success depends on obtaining regulatory approvals for its ADC candidates, which is a complex and uncertain process. The biotechnology industry is highly competitive, with many companies developing similar therapies.
How does Advanced Proteome Therapeutics Corporation navigate regulatory approval processes?
Advanced Proteome Therapeutics Corporation, as a biotechnology company, must navigate rigorous regulatory approval processes to bring its protein therapeutics to market. This primarily involves working with regulatory agencies such as the FDA in the United States. The company must demonstrate the safety and efficacy of its products through preclinical and clinical trials.
What revenue streams does Advanced Proteome Therapeutics Corporation have in healthcare?
As an early-stage biotechnology company, Advanced Proteome Therapeutics Corporation currently has limited revenue streams. Potential future revenue streams could include upfront payments, milestone payments, and royalties from licensing its proprietary platform for chemical modification of protein therapeutics to other biotechnology and pharmaceutical companies.
What are the key factors to evaluate for APTCF?
Advanced Proteome Therapeutics Corporation (APTCF) holds an AI score of 44/100 (low). P/E: 0.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does APTCF data refresh on this page?
APTCF's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven APTCF's recent stock price performance?
Advanced Proteome Therapeutics Corporation (APTCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary platform for chemical modification of protein therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis pending for APTCF.